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Background.  —  The  ideal  duration  of  dual  antiplatelet  therapy  (DAPT)  after  percutaneous  coro-
nary intervention  (PCI)  is  under  debate.  Lesion  length  is  a  well-recognized  predictor  of  PCI
complexity and  long-term  outcome.
Aim.  —  To  evaluate  the  determinants  and  impact  on  outcome  of  long-term  DAPT  in  a  retrospec-
tive cohort  of  patients  treated  for  a  long  coronary  lesion.
Abbreviations: CAD, Coronary artery disease; CI, Conﬁdence interval; DAPT, Dual antiplatelet therapy; DES, Drug-eluting stent; HR,
Hazard ratio; LVEF, Left ventricular ejection fraction; SAPT, Single antiplatelet therapy; PCI, Percutaneous coronary intervention.
∗ Corresponding author. Centre hémodynamique et unité de soins intensifs de cardiologie, hôpital Cardiologique, boulevard du Pr-Jules-
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Methods.  —  Patients  (n  =  460)  who  underwent  PCI  for  a  long  lesion  (>  30  mm)  were  divided  into
two groups  according  to  antiplatelet  regimen  at  1  year:  patients  who  stopped  DAPT  before
1 year  (single  antiplatelet  therapy  group;  n  =  168)  and  patients  who  continued  DAPT  for  longer
than 1  year  (n  =  292).
Results.  —  Mean  lesion  length  was  35.7  ±  7.1  mm.  The  proportion  of  patients  who  continued
DAPT after  1  year  was  63.5%.  The  main  determinants  of  long-term  DAPT  were  initial  presenta-
tion as  myocardial  infarction  and  implantation  of  a  drug-eluting  stent.  Median  follow-up  was
37.4 (23—51)  months  after  the  1-year  period  following  the  index  PCI.  Long-term  DAPT  was
highly associated  with  a  lower  risk  of  all-cause  and  cardiovascular  mortality  by  multivariable
analysis  and  after  adjustment  for  other  predictors:  hazard  ratios  0.11  (95%  conﬁdence  interval
0.03—0.32) and  0.15  (95%  conﬁdence  interval  0.04—0.62),  respectively.  No  increase  in  major
bleeding  was  noted.
Conclusion.  —  In  a  contemporary  practice,  nearly  two-thirds  of  patients  who  undergo  PCI  for  a
long lesion  are  treated  with  DAPT  for  several  years.  Our  results  suggest  that  long-term  DAPT  is
beneﬁcial  in  this  subset  of  patients  identiﬁed  as  being  at  high  risk.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  durée  exacte  du  maintien  de  la  double  anti-agrégation  plaquettaire  (DAAP)
après une  angioplastie  coronaire  percutanée  (ACP)  est  débattue.  La  longueur  des  lésions  coro-
naires traitées  est  un  facteur  bien  connu  de  la  complexité  des  ACP  et  du  pronostic  à  long
terme.
Objectifs. — Nous  avons  réalisé  une  étude  rétrospective  des  patients  traités  pour  une  longue
lésion coronaire  aﬁn  d’évaluer  la  proportion  de  patients  traités  par  DAAP  après  1  an  dans  cette
population,  les  facteurs  déterminants  de  cette  prescription  et  l’impact  sur  le  pronostic  des
patients.
Méthodes. — Quatre  cent  soixante  patients,  ayant  eu  une  ACP  pour  une  lésion  de  plus  de  30  mm,
ont été  inclus  et  divisés  en  2  groupes  en  fonction  de  leur  régime  anti-agrégant  plaquettaire  à
1 an.  Les  patients  ayant  stoppé  la  DAAP  avant  1  an  (groupe  MAPT  ;  n  =  168)  ont  été  comparés  à
ceux qui  ont  poursuivi  la  DAAP  au-delà  de  1  an  (groupe  DAPT  ;  n  =  292).
Résultats.  — La  longueur  moyenne  des  lésions  était  de  35,7  ±  7,1  mm.  La  proportion  de  patients
traités par  DAAP  après  1  an  était  de  63,5  %.  Les  facteurs  déterminants  de  cette  prescription
étaient la  présentation  clinique  initiale  (syndrome  coronaire  aigu)  et  l’implantation  d’un  stent
actif. Le  délai  médian  de  suivi  était  de  37,4  mois  après  la  période  de  1  an  faisant  suite  à  l’ACP
initiale. Le  traitement  DAAP  prolongé  était  associé  à  un  taux  plus  faible  de  mortalité  toute
cause et  cardiovasculaire  en  analyse  multivariée  :  HR  =  0,11  (0,03—0,32)  et  0,15  (0,04—0,62),
respectivement.  On  notait  l’absence  d’augmentation  signiﬁcative  du  risque  de  saignement.
Conclusion.  —  Dans  une  pratique  contemporaine,  près  de  deux  tiers  des  patients  ayant  une
ACP pour  une  longue  lésion  coronaire  sont  traités  par  DAAP  prolongée.  Nos  résultats  suggèrent
qu’une DAAP  prolongée  serait  bénéﬁque  dans  cette  population  particulière  identiﬁée  à  haut
risque.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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ntiplatelet  therapy  is  a  cornerstone  treatment  in  patients
ith  coronary  artery  disease  (CAD).  Aspirin  use  has  been
nown  for  some  time  to  produce  a  signiﬁcant  reduction  in
orbidity  and  mortality  rates  in  such  patients,  and  is  subse-
uently  widely  used  in  secondary  prevention  [1].  In  addition,
ual  antiplatelet  therapy  (DAPT),  combining  aspirin  and  a
2Y12 receptor  antagonist,  is  the  treatment  of  choice  for
atients  with  acute  manifestations  of  CAD,  acute  coronary
g
o
tyndromes  and/or  percutaneous  coronary  intervention  (PCI)
2—5].  According  to  the  guidelines,  DAPT  should  be  contin-
ed  in  these  settings  for  6—12  months;  thereafter,  patients
hould  be  switched  to  single  antiplatelet  therapy  (SAPT),
hich  is  currently  the  recommended  lifelong  treatment  in
atients  with  stable  CAD  [6,7].In  2006,  concerns  were  raised  about  the  safety  of  ﬁrst-
eneration  drug-eluting  stents  (DESs)  in  terms  of  the  risk
f  late/very  late  stent  thrombosis  and  long-term  mor-
ality  [8—14]. Hence,  the  duration  of  DAPT  after  DES
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implantation  has  been  increased  progressively  in  clinical
practice,  with  sometimes  wide  local  differences.  In  low-risk
populations,  recent  randomized  trials  have  suggested  that
long-term  DAPT  (beyond  6—12  months)  may  not  be  beneﬁcial
in  patients  undergoing  PCI  with  DES  implantation  [15—20].
In  contrast,  several  well-conducted  registries  and  a  substudy
of  the  PRODIGY  trial,  focusing  on  the  stent  thrombosis  issue
and  including  higher-risk  patients,  have  suggested  that  some
individuals  may  require  lifelong  DAPT  [21—28].  To  date,  the
exact  duration  of  DAPT  after  DES  implantation  is  largely  the
subject  of  debate  in  the  literature.  Some  authors  suggest
individual  adaptation  of  the  duration  of  DAPT  after  PCI.  The
length  of  a  coronary  artery  lesion  is  a  well-recognized  pre-
dictor  of  PCI  complexity  and  long-term  outcome,  especially
regarding  the  risk  of  stent  thrombosis  and  death  [23,29,30].
We  therefore  investigated  a  cohort  of  patients  treated
for  a  long  coronary  artery  lesion  (>  30  mm),  to  evaluate  the
proportion  of  patients  receiving  DAPT  after  1  year  in  this
speciﬁc  population,  the  determinants  of  long-term  DAPT  and
the  impact  of  such  a  strategy  on  mortality.
Methods
Population and study design
Between  April  2007  and  December  2011,  573  patients  were
included  in  this  retrospective  cohort.  Patients  were  eligi-
ble  if  they  underwent  successful  PCI  in  our  centre  (Lille,
France),  with  implantation  of  either  at  least  one  bare-metal
stent  or  at  least  one  DES  for  the  treatment  of  a  long  lesion
(deﬁned  as  a  lesion  >  30  mm  in  length).  In  case  of  multiple
stent  implantations,  all  stents  had  to  have  been  implanted
using  the  overlap  technique;  patients  with  any  gaps  between
several  stents  were  excluded  (n  =  2).  For  reasons  of  clar-
ity  and  homogeneity,  patients  treated  with  different  types
of  stents  (especially  bare-metal  stents  and  DESs)  for  the
same  lesion  were  excluded  (n  =  37).  In  addition,  as  previous
anticoagulation  treatment  is  often  responsible  for  DAPT  dis-
continuation  within  the  ﬁrst  year  after  PCI,  patients  treated
with  vitamin  K  antagonists  were  excluded  (n  =  32).  Patients
who  experienced  major  bleeding  and/or  surgery  within  the
ﬁrst  year  after  PCI  were  excluded  for  the  same  reason
(n  =  10).  Finally,  patients  who  died  and/or  experienced  an
acute  coronary  syndrome  and/or  underwent  another  PCI
within  the  ﬁrst  year  after  the  index  PCI  were  excluded
(n  =  45).  Only  event-free  patients  at  1  year  were  included.
One  individual  could  ﬁt  different  exclusion  criteria.
The  ﬁnal  population  (n  =  460)  was  divided  in  two  groups
according  to  the  antiplatelet  regimen  that  patients  were
receiving  1  year  after  PCI  (Fig.  1).  Patients  who  stopped
DAPT  before  1  year  (SAPT  group;  n  =  168)  were  compared
with  those  who  continued  DAPT  after  1  year  (DAPT  group;
n  =  292).  The  median  duration  of  DAPT  in  the  SAPT  group
was  10.8  months  (6.5—12  months).
Percutaneous coronary intervention
proceduresPCI  with  coronary  stent  implantation  was  performed  in
accordance  with  the  standard  technique  used  in  our
catheterization  laboratory,  and  all  patients  gave  informed
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onsent  [2]. All  patients  were  pretreated  with  an  intra-
enous  bolus  of  aspirin  (250—500  mg)  and  an  intravenous
olus  of  heparin  (50—70  IU/kg);  they  also  received  a  loading
ose  of  clopidogrel  (300—600  mg).  The  use  of  glycoprotein
Ib/IIIa  inhibitors  was  at  the  discretion  of  the  physician.  After
he  procedure,  patients  were  treated  with  aspirin  75  mg
nd  clopidogrel  75  mg  once  daily  until  the  discontinuation
f  DAPT  (i.e.  clopidogrel).
ata collection
aseline  characteristics  were  indexed  after  systematic  in-
ospital  chart  review.  Index  coronary  angiograms  were
eviewed  by  two  experienced  interventional  cardiologists
linded  to  patient  outcome  (C.D.  and  G.L.).
All  patients  or  their  immediate  family  were  interviewed
y  telephone.  In  case  of  inaccurate  and/or  incomplete
nswers,  general  practitioners  and  cardiologists  were  con-
acted  to  complete  information.  Of  note,  information  on
ntiplatelet  therapy  and  antithrombotic  regimens  was  care-
ully  collected.  When  clopidogrel  discontinuation  occurred,
e  obtained  the  exact  date  of  DAPT  discontinuation  in  77%
f  cases.  For  the  remaining  patients,  the  exact  month  of  dis-
ontinuation  was  available  in  all  cases;  in  these  cases,  the
5th  of  the  month  was  automatically  indexed  as  the  date  of
APT  discontinuation.  A date  of  cessation  was  subsequently
vailable  for  100%  of  the  patients  who  stopped  DAPT  within
he  ﬁrst  year  after  PCI.
bjective, follow-up, deﬁnitions and
ndpoints
he  main  objective  of  the  present  study  was  to  assess  the
mpact  of  long-term  DAPT  on  prognosis  in  patients  treated
or  a  long  coronary  artery  lesion.
Clinical  follow-up  was  performed  at  outpatient  ofﬁce
isits  or  by  telephone  contact  with  the  patient  and/or  their
eneral  practitioner  or  cardiologist.  The  median  follow-up
as  37.4  months  (23—51  months)  after  the  1-year  period  fol-
owing  the  index  PCI  in  the  overall  population,  35.7  months
18—52  months)  in  the  SAPT  group  and  38.3  months
22—54  months)  in  the  DAPT  group.  We  collected  data  on
eath,  stent  thrombosis  and  bleeding.  All  clinical  events
ere  adjudicated  blindly  by  at  least  two  investigators  in  all
ases  and  by  three  investigators  in  case  of  disagreement,
ccording  to  prespeciﬁed  deﬁnitions.  In  case  of  new  hospi-
alization,  data  were  obtained  by  a  systematic  review  of  the
ischarge  letter.  The  cause  of  death  was  determined  after
 detailed  review  of  the  circumstances  of  death,  and  was
lassiﬁed  as  cardiovascular  or  non-cardiovascular.  Deaths
rom  unknown  causes  were  classiﬁed  as  cardiovascular.
ajor  bleeding  was  deﬁned  as  the  occurrence  of  a  fatal
aemorrhage  and/or  an  intracranial  haemorrhage  and/or  a
eed  for  transfusion  and/or  a  decrease  in  the  haemoglobin
oncentration  of  ≥  5  g/dL  or  a  ≥  15%  decrease  in  haemat-
crit.  Minor  bleeding  was  deﬁned  as  the  occurrence  of  a
eripheral  vascular  complication  and/or  other  symptomatic
aemorrhagic  complication  without  any  major  bleeding
eﬁnition  criteria  and/or  a  decrease  in  the  haemoglobin
oncentration  of  3  g/dL  (but  <  5  g/dL)  or  a  10%  (but  <  15%)
ecrease  in  haematocrit.
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migure 1. Flow chart of the study.
The  primary  endpoint  was  all-cause  death;  secondary
ndpoints  were  cardiovascular  death  and  bleeding.
tatistical analysis
ontinuous  variables  are  expressed  as  means  ±  standard
eviations.  Categorical  variables  are  expressed  as  absolute
umbers  and  percentages.  Durations  are  expressed  as  medi-
ns  with  25th  and  75th  percentiles.
To  evaluate  predictors  of  long-term  DAPT,  baseline  char-
cteristics  in  the  SAPT  and  DAPT  groups  were  compared
sing  the  Chi2 test  or  Fisher’s  test  for  categorical  variables
nd  Student’s  unpaired  t-test  for  continuous  variables,  as
ppropriate.
To  evaluate  the  impact  of  long-term  DAPT  on  patient  out-
omes,  predictors  of  events  were  analysed  using  a  univariate
ox  analysis;  a  multivariable  analysis  was  then  performed.
ll  data  with  a  P  value  <  0.2  in  the  univariate  analysis  were
ntered  in  a  forward  stepwise  manner  into  a  Cox  multivari-
ble  model,  with  entry  and  retention  set  at  a  signiﬁcance
evel  of  0.05.  Cox  proportional  hazard  analyses  were  per-
ormed  to  calculate  hazard  ratios  (HRs)  and  95%  conﬁdence
ntervals  (CIs).  Co-linearity  was  excluded  by  means  of  a  cor-
elation  matrix  between  candidate  predictors.  Cumulative
vent  rates  in  both  groups  (SAPT  and  DAPT)  were  estimated
sing  the  Kaplan—Meier  method  and  compared  using  the
og-rank  test.
All  statistical  analyses  were  performed  using  SPSS® soft-
are  for  Windows,  version  20.0  (SPSS  Inc.,  Chicago,  IL,  USA).
tatistical  signiﬁcance  was  assumed  at  a  P  value  <  0.05.
The  authors  had  full  access  to  the  data  and  take  respon-
ibility  for  their  integrity.  All  authors  have  read  and  agree
o  the  manuscript  as  written.
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aseline  clinical,  procedural  and  angiographical  charac-
eristics  are  summarized  in  Tables  1—3.  In  the  overall
opulation  (n  =  460),  the  mean  age  was  65.7  ±  12  years,
6.9%  of  patients  were  men  and  33.2%  were  diabetics.  Only
0%  of  patients  had  a  history  of  myocardial  infarction,  15.9%
ad  a  history  of  PCI  and  9.5%  had  a history  of  coronary  artery
ypass  graft  surgery.  The  mean  left  ventricular  ejection  frac-
ion  (LVEF)  was  51.8  ±  8.9%.
The  indication  of  the  index  PCI  was  an  acute  myocardial
nfarction  in  36.1%  of  cases,  including  19.5%  with  ST-segment
levation  myocardial  infarction.
The  mean  lesion  length  was  35.7  ±  7.1  mm  and  the  mean
eference  vessel  diameter  was  3.1  ±  0.5  mm.  The  mean
umber  of  stents  per  lesion  was  1.8  ±  0.6  and  33.7%  of  the
esions  required  >  1  stent  implantation.  A  DES  was  implanted
n  83.2%  of  cases.  The  lesion  location  was  the  left  anterior
escending  coronary  artery  in  53.0%  of  cases.
requency and determinants of long-term
ual antiplatelet therapy
he  proportion  of  patients  who  continued  with  long-term
APT  after  1  year  following  the  index  PCI  was  high  in  this
elected  population,  at  63.5%.
In  univariate  analysis  and  as  shown  in  Tables  1—3,  the
ain  determinants  of  long-term  DAPT  in  our  selected  pop-
lation  were  initial  clinical  presentation  as  myocardial
nfarction  (P  =  0.004),  either  with  or  without  ST-segment
levation,  DES  implantation  (P  =  0.001)  and  a  lower  pre-
rocedural  stenosis  percentage  (P  =  0.011);  these  were  all
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Table  1  Baseline  demographic  and  clinical  characteristics  of  the  overall  population  and  of  the  two  groups  according  to
their  antiplatelet  therapy  regimen.
Overall  population
(n  =  460)
SAPT
(n =  168)
DAPT
(n =  292)
P
Men  354  (76.9)  126  (75.0)  228  (78.1)  0.59
Age  (years)  65.7  ±  12.0  66.3  ±  12.8  64.5  ±  11.6  0.13
Dyslipidaemia  293  (63.7)  101  (60.1)  192  (65.7)  0.55
Smokers  160  (34.8) 59  (35.1)  101  (34.6)  0.74
Hypertension  267  (58.0) 99  (58.9) 168  (57.5)  0.70
Cardiovascular  heredity 143  (31.1) 49  (29.2) 94  (32.2) 0.36
Body  mass  index  (kg/m2) 28.7 ±  13.9 27.9  ±  5.5 29.2  ±  16.9 0.32
Diabetes  153  (33.2)  49  (29.2)  104  (35.6)  0.24
Stroke  18  (3.9)  4  (2.4)  14  (4.8)  0.21
History  of  CAD  222  (48.3)  75  (44.6)  147  (50.3)  0.29
Prior  myocardial  infarction  138  (30.0)  46  (27.4)  92  (31.5)
Prior  PCI 73 (15.9) 53  (31.5) 20  (6.8)
Prior  CABG 44  (9.5) 19  (11.3) 25  (8.6)
Peripheral  vascular  disease  47  (10.2)  13  (7.7)  34  (11.6)  0.32
Renal  failure  (creatinine  clearance  ≤  60  mL/min)  38  (8.3)  16  (9.5)  22  (7.5)  0.30
Initial  clinical  presentation  as  myocardial  infarction  166  (36.1)  74  (44.0)  92  (31.5)  0.004
With  ST-segment  elevation  89  (19.5)  39  (23.2)  50  (17.1)
Without  ST-segment  elevation  77  (16.5)  35  (21.5)  42  (14.4)
LVEF  (%)  51.8  ±  8.9  51.4  ±  9.5  52  ±  8.4  0.57
LVEF  ≥  45%  223  (48.5)  83  (49.4)  140  (47.9)  0.71
Creatinine  (mg/L)  9.9  ±  3.9  10.3  ±  5.3  9.6  ±  2.9  0.06
Total  cholesterol  (mmol/L)  4.4  ±  1.3  4.6  ±  1.3  4.3  ±  1.3  0.28
LDL  cholesterol  (mmol/L)  2.5  ±  1.1  2.6  ±  0.1.1  2.4  ±  1.1  0.13
HDL  cholesterol  (mmol/L)  1.2  ±  0.5  1.2  ±  0.5  1.2  ±  0.5  0.67
Triglycerides  (mmol/L)  2.5  ±  1.1  1.7  ±  0.9  2.9  ±  1.2  0.42
Data are number (%) or mean ± standard deviation. CABG: coronary artery bypass graft; CAD: coronary artery disease; DAPT: dual
antiplatelet therapy; HDL: high-density lipoprotein; LDL: low-density lipoprotein; LVEF: left ventricular ejection fraction; SAPT: single
antiplatelet therapy; PCI: percutaneous coronary intervention.
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tsigniﬁcantly  associated  with  long-term  DAPT.  Interestingly,
there  was  also  a  trend  towards  more  frequent  use  of
the  Rotablator® technique  and  a  higher  radiation  dose  in
patients  receiving  long-term  DAPT,  suggesting  more  complex
lesions.
Impact of long-term dual antiplatelet therapy
on outcome
The  median  follow-up  was  37.4  months  (23—51  months)  after
the  1-year  period  following  the  index  PCI  in  the  overall
population,  35.7  months  (18—52  months)  in  the  SAPT  group
and  38.3  months  (22—54  months)  in  the  DAPT  group.  There
were  26  (5.6%)  all-cause  deaths  and  19  (4.1%)  cardiovascu-
lar  deaths  during  follow-up  in  the  overall  population.  There
were  only  four  late  and/or  very  late  stent  thromboses  in
our  population,  making  this  criterion  uninterpretable.  As
shown  in  Table  4  and  Figs.  2  and  3,  patients  treated  with
DAPT  for  >  12  months  had  a  signiﬁcantly  lower  risk  of  death
from  all-causes  (1.7%  vs.  12.5%,  HR  0.12,  95%  CI  0.04—0.32;
P  <  0.0001)  and  from  cardiovascular  causes  (1.7%  vs.  8.3%,
HR  0.19,  95%  CI  0.06—0.51;  P  =  0.001).
Interestingly,  there  was  only  one  patient  (in  the  DAPT
group)  who  experienced  major  bleeding  during  follow-up
in  our  speciﬁc  population.  The  rate  of  minor  bleeding  was
i
e
c
aot  signiﬁcantly  different  between  the  two  groups;  a  trend
owards  more  minor  bleeding  was  observed  in  the  DAPT
roup  (26.3%  vs.  19.0%,  HR  1.52,  95%  CI  0.98—1.15;  P  =  0.06)
Table  4).
Of most  importance,  long-term  DAPT  was  still  sig-
iﬁcantly  associated  with  a  lower  risk  of  all-cause  and
ardiovascular  mortality  by  multivariable  analysis  and
fter  adjustment  for  other  predictors:  HR  0.11,  95%  CI
.03—0.32  (P  <  0.0001)  for  all-cause  mortality;  HR  0.15,
5%  CI  0.04—0.62  (P  =  0.009)  for  cardiovascular  mortality
Tables  5  and  6).
iscussion
ur  contemporary  study,  which  involved  patients  treated
etween  2007  and  2011,  reports  that,  despite  recent  inter-
ational  recommendations,  a  very  high  proportion  (around
wo-thirds)  of  patients  with  long  coronary  artery  lesions
>  30  mm)  are  treated  with  long-term  DAPT.  Of  most  impor-
ance,  our  results  also  suggest  that  long-term  DAPT  after  PCI
s  beneﬁcial  in  this  speciﬁc  subset  of  patients  at  high  risk  of
vents.  We  found  a  signiﬁcant  reduction  in  all-cause  and
ardiovascular  mortality  at  a  median  follow-up  of  >  4  years
fter  the  index  PCI.
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Table  2  Baseline  procedural  characteristics  of  the  overall  population  and  of  the  two  groups  according  to  their
antiplatelet  therapy  regimen.
Overall  population
(n  =  460)
SAPT
(n =  168)
DAPT
(n  =  292)
P
Scope  duration  (seconds)  526.3  ±  143.2  503.7  ±  196.3  539.6  ±  94.3  0.64
Radiation  dose  (Gy/m2)  107.4  ±  62.4  97.2  ±  61.3  113.9  ±  62.8  0.05
Procedural  duration  (minutes)  54.1  ±  25.2  52.1  ±  24.5  54.5  ±  25.7  0.33
Quantity  of  contrast  media  (mL) 192.1  ±  74.9 190.0  ±  72.6 194.3  ±  76.8  0.62
Kissing  technique 90  (19.6) 31  (18.4) 59  (20.2) 0.69
Thromboaspiration  40  (8.7) 18  (10.7) 22  (7.5) 0.23
Rotablator  15  (3.3)  2 (1.2)  13  (4.4)  0.06
Data are number (%) or mean ± standard deviation. DAPT: dual antiplatelet therapy; SAPT: single antiplatelet therapy.
Table  3  Baseline  angiographical  characteristics  of  the  index  treated  lesion  in  the  overall  population  and  in  the  two
groups  according  to  their  antiplatelet  therapy  regimen.
Overall  population
(n  =  460)
SAPT
(n  =  168)
DAPT
(n  =  292)
P
Lesion  location
Bypass  9  (1.9)  5  (2.9)  4  (1.4)
Left  main  coronary  artery  15  (3.3)  10  (5.9)  5  (1.7)
LAD  244  (53.0)  84  (50.0)  160  (54.8)  0.39
Others  192  (41.7)  69  (41.1)  123  (42.1)
Lesion  length  (mm)  35.7  ±  7.1  35.7  ±  6.8  35.8  ±  7.3  0.92
RVD  (mm)  3.1  ±  0.5  3.1  ±  0.5  3.1  ±  0.5  0.69
Number  of  stents  per  lesion  1.8  ±  0.6  1.8  ±  0.6  1.8  ±  0.6  0.96
Number  of  lesions  treated  with  >  1  stent  155  (33.7)  55  (32.7)  100  (34.2)  0.81
Preprocedural  MLD  (mm)  0.6  ±  0.6  0.6  ±  0.6  0.6  ±  0.6  0.43
Preprocedural  stenosis  percentage  (%)  80.0  ±  14.4  82.3  ±  13.1  78.7  ±  15.0  0.01
Post-procedural  MLD  (mm)  3.0  ±  0.5  3.0  ±  0.7  2.9  ±  0.5  0.23
Post-procedural  stenosis  percentage  (%)  4.9  ±  1.63  5.8  ±  1.7  4.3  ±  1.6  0.28
Stent  type
Bare-metal  stent  67  (14.6)  36  (21.4)  31  (10.6)
Drug-eluting  stent  383  (83.2)  129  (76.8)  254  (86.9)  0.001
Cypher® 230  (50.0)  76  (45.4)  154  (52.7)
Taxus® 101  (21.9) 36  (21.4)  65  (22.2)
Promus® 24  (5.2)  8  (4.7)  16  (5.5)
Endeavor® 28  (6.1)  9  (5.3)  19  (6.5)
Others  10  (2.2)  3  (1.8)  7  (2.5)
Data are number (%) or mean ± standard deviation. DAPT: dual antiplatelet therapy; LAD: left anterior descending coronary artery;
SAPT: single antiplatelet therapy; MLD: minimal lumen diameter; RVD: reference vessel diameter.
Table  4  Rates  of  events  in  the  overall  population  and  in  the  two  groups  according  to  their  antiplatelet  therapy  regimen
(univariate  Cox  analysis).
Overall  population
(n  =  460)
SAPT
(n  =  168)
DAPT
(n  =  292)
HR  (95%  CI)  P
All-cause  death  26  (5.6)  21  (12.5)  5  (1.7)  0.12  (0.04—0.32)  <  0.0001
Cardiovascular  death  19  (4.1)  14  (8.3)  5  (1.7)  0.19  (0.06—0.51)  0.001
Bleeding
Major  bleeding  1  (0.2)  0  (0.0)  1  (0.3)  NA  NA
Minor  bleeding  109  (23.6)  32  (19.0)  77  (26.3)  1.52  (0.98—1.15)  0.06
Data are number (%). CI: conﬁdence interval; DAPT: dual antiplatelet therapy; HR: hazard ratio; SAPT: single antiplatelet therapy; NA:
not applicable.
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SAPT
Figure 2. Cumulative freedom from all-cause mortality curves in
each group. Single antiplatelet therapy (SAPT) = dotted line; dual
antiplatelet therapy (DAPT) = solid line. HR: hazard ratio; PCI: per-
cutaneous coronary intervention.
SAPT
Figure 3. Cumulative freedom from cardiovascular mortality
curves in each group. Single antiplatelet therapy (SAPT) = dotted
Table  5  Multivariable  analysis  for  all-cause  mortality:
Cox  proportional  hazard  analyses  were  performed  to  cal-
culate  hazard  ratios  and  95%  conﬁdence  intervals.
HR  (95%  CI)  P
DAPT  ≥  12  months  0.11  (0.03—0.32) <  0.0001
Age,  per  year  1.03  (1.00—1.05) 0.047
Creatinine  concentration,
per  mg/L
1.09  (1.00—1.18) 0.042
History  of  CAD 3.41  (1.29—8.80) 0.012
Stroke  9.10  (2.21—33.91) 0.001
LVEF,  per  percentage 0.93  (0.84—0.98) 0.011
RVD,  per  additional
0.1  mm
1.41 (1.05—1.99) 0.006
CAD: coronary artery disease; CI: conﬁdence interval; DAPT: dual
antiplatelet therapy; HR: hazard ratio; LVEF: left ventricular
ejection fraction; RVD, reference vessel diameter.
Table  6  Multivariable  analysis  for  cardiovascular  mor-
tality:  Cox  proportional  hazard  analyses  were  performed
to  calculate  hazard  ratios  and  95%  conﬁdence  intervals.
HR  (95%  CI) P
DAPT  ≥  12  months  0.15  (0.04—0.62) 0.009
Age,  per  year  1.07  (1.01—1.13) 0.015
Stroke  9.39  (1.71—50.60)  0.009
RVD,  per  additional
0.1  mm
1.83  (1.09—3.61) 0.005
CAD: coronary artery disease; CI: conﬁdence interval; DAPT:
dual antiplatelet therapy; HR: hazard ratio; RVD, reference
vessel diameter.
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PCI: percutaneous coronary intervention.
Risk in our population
It  is  very  important  to  note  that  the  inclusion  and  exclu-
sion  criteria  in  the  present  study  led  to  the  selection  of  a
highly  speciﬁc  population,  which  was  at  particularly  high
risk  of  ischaemic  events  on  the  one  hand,  but  at  low  risk
of  major  bleeding  on  the  other.  Of  note,  33.2%  of  patients
in  our  cohort  were  diabetic,  36.1%  initially  presented  with
L
c
myocardial  infarction  (19.5%  with  ST-segment  elevation
yocardial  infarction),  and  48.5%  had  an  LVEF  ≤  45%  (mean
VEF  of  51.8%).  In  recent  randomized  trials  published  in  the
eld  of  DAPT  duration  after  PCI,  patients  usually  present  a
ower  risk  proﬁle.  In  the  population  studied  by  Lee  et  al.
19], around  25%  were  diabetic,  with  a normal  LVEF,  and
nly  12.5%  of  patients  presented  with  ST-segment  elevation
yocardial  infarction.  In  the  PRODIGY  study  [20],  only  23%  of
atients  were  diabetic.  Patients  included  in  the  EXCELLENT
nd  RESET  trials  also  had  low-risk  proﬁles,  with  a  normal
VEF,  and  only  2%  and  14%,  respectively,  had  ST-segment
levation  myocardial  infarction  [17,18].
Of  note,  all  patients  had  to  have  a  long  coronary  artery
esion  (>  30  mm)  to  be  included  in  the  present  cohort,  and
he  mean  lesion  length  was  around  36  mm,  which  is  much
onger  than  that  usually  observed  in  randomized  trials  in
his  ﬁeld  (mean  22—30  mm)  [17,18,20]. This  led  to  the
election  of  patients  with  more  complex  lesions:  a high  pro-
ortion  of  bifurcation  (20%)  and  a  high  number  of  stents
er  lesion  (mean  1.8).  The  characteristics  of  the  lesions
n  our  study  were  very  close  to  those  usually  observed  in
tudies  focusing  on  long  coronary  artery  lesions  [29—33].
ong  lesions  have  always  been  associated  with  poor  out-
ome,  with  higher  rates  of  stent  thrombosis,  restenosis  and
ortality  [23,29,30].  Interestingly,  the  rate  of  death  was
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ubsequently  much  higher  in  our  study  (5.6%)  compared
ith  that  in  most  other  trials  in  this  ﬁeld  (between  0.5%
nd  2%)  [17—19],  except  the  PRODIGY  study  (6.6%,  but  this
ate  includes  events  that  occurred  within  the  ﬁrst  year  of
ollow-up  after  the  index  PCI)  [20].
Even  more  importantly,  patients  receiving  vitamin  K
ntagonists  and  those  who  experienced  major  bleeding
nd/or  surgery  within  the  ﬁrst  year  after  PCI  (situations  that
sually  lead  to  early  cessation  of  antiplatelet  therapy)  were
ystematically  excluded  from  the  present  analysis,  resulting
n  the  selection  of  patients  at  low  bleeding  risk.  Indeed,  only
ne  patient  experienced  major  bleeding  during  follow-up  in
ur  study.  This  is  not  usually  the  case  in  randomized  trials  in
his  ﬁeld,  because  patients  are  usually  randomized  at  time
f  the  index  PCI  and  not  after  1  year  [17,18,20].  The  only
andomized  trial  that  included  event-free  patients  at  1 year
as  we  did  here)  reported  a  very  low  rate  of  major  bleeding
around  1%),  in  accordance  with  our  results  [19].  Of  note,
he  rate  of  major  bleeding  was  similar  in  patients  receiving
ong-term  DAPT  and  those  receiving  SAPT  in  this  study  of
ore  than  5000  patients  [19].
eterminants of long-term dual antiplatelet
herapy
he  design  of  our  study  (in  contrast  to  randomized  tri-
ls)  allows  analysis  of  the  clinical  determinants  of  such  a
trategy  in  everyday  clinical  practice.  As  expected,  patients
ho  underwent  DES  implantation  for  the  treatment  of  CAD
ere  more  often  receiving  long-term  DAPT.  The  warning
egarding  the  risk  of  late  and  very  late  events,  especially
tent  thrombosis,  after  ﬁrst-generation  DES  implantation
ay  have  played  a  pivotal  role  in  physician  attitude  [8—14].
side  from  the  type  of  implanted  stent,  the  lesion  complex-
ty  may  also  have  led  to  a  longer  DAPT  duration.  Indeed,
he  dose  of  radiation,  the  preprocedural  stenosis  percentage
nd  the  rate  of  the  Rotablator® technique  use,  all  markers  of
esion  complexity,  were  associated  with  long-term  DAPT  in
ur  cohort.  Finally,  the  indication  of  the  index  PCI  was  also
ssociated  with  the  decision  about  whether  or  not  to  pursue
ong-term  DAPT.  Patients  presenting  with  myocardial  infarc-
ion  as  the  indication  for  the  index  PCI  were  more  frequently
witched  to  SAPT  at  1  year  with  no  clear  explanation.
mpact of long-term dual antiplatelet therapy
n mortality
nfortunately,  our  study  was  not  sufﬁciently  powered  to
nalyse  the  outcome  of  stent  thrombosis.  In  our  selected
opulation,  however,  we  found  that  all-cause  and  cardio-
ascular  mortalities  were  both  signiﬁcantly  decreased  in
atients  receiving  long-term  DAPT  compared  with  those
ho  were  switched  to  SAPT.  This  beneﬁt  was  still  statisti-
ally  signiﬁcant  after  adjustment  by  multivariable  analysis
or  other  predictors  of  mortality.  These  results  contrast
ith  the  results  of  recent  randomized  trials  that  did  not
how  any  beneﬁt  of  long-term  DAPT  in  unselected  and  low-
isk  PCI  populations  [15—20].  The  results  are,  however,  in
greement  with  several  well-conducted  registries  and  a  sub-
tudy  of  the  PRODIGY  trial  focusing  on  the  stent  thrombosis
ssue  and  including  high-risk  patients,  which  reported  aA.  Manchuelle  et  al.
etrimental  effect  of  early  clopidogrel  cessation  after  PCI
ith  ﬁrst-generation  DES  implantation  [21—28].  These  data,
ollectively,  suggest  that  DAPT  duration  may  require  adapta-
ion  with  regard  to  the  speciﬁc  risk  of  each  individual:  ‘‘one
uration  may  not  ﬁt  all’’.  If  early  discontinuation  of  clopid-
grel  seems  possible  in  most  low-risk  patients  and  should  be
he  rule  rather  than  the  exception,  as  suggested  by  recent
andomized  studies  [15—20]  and  European  guidelines  on  sta-
le  angina  [34],  our  results  also  suggest  that  exceptional
ases  who  may  beneﬁt  from  long-term  DAPT  should  not  be
orgotten,  and  that  conclusions  are  less  hazardous  for  high-
isk  patients.
tudy limitations
he  non-randomized  design  of  our  study  is  the  principal  lim-
tation  when  it  comes  to  analysing  the  impact  of  long-term
APT  on  patient  prognosis.  In  addition,  the  reasons  for  clo-
idogrel  cessation  in  those  patients  who  were  switched  to
APT  were  not  available  for  the  present  analysis,  and  may
e  related  to  uncontrolled  bias.  The  important  difference
n  mortality  observed  between  groups  may,  in  consequence,
e  overestimated  and  not  only  related  to  antiplatelet  ther-
py  regimen.  The  design,  however,  enabled  the  inclusion  of
 very  high-risk  population  and  the  study  of  determinants
f  long-term  DAPT.  Finally,  it  is  also  very  important  to  note
hat  a  long  coronary  artery  lesion  is  not  a  rare  situation  in
linical  practice  and  usually  represents  up  to  25%  of  all  PCIs
n  registries  [29,30].  Nevertheless,  these  patients  are  rarely
ncluded  in  randomized  trials  evaluating  the  impact  of  long-
erm  DAPT  on  patient  outcome,  and  no  data  are  currently
vailable  in  this  subset  of  patients.
onclusion
n  a  contemporary  practice,  it  is  very  interesting  to  note
hat  nearly  two-thirds  of  patients  who  undergo  PCI  for  a
ong  coronary  artery  lesion  are  treated  with  DAPT  for  several
ears.  Our  study  suggests  that  long-term  DAPT  is  beneﬁcial
n  this  speciﬁc  subset  of  patients  identiﬁed  at  being  at  high
isk  of  ischaemic  events,  and  that  DAPT  duration  should  be
ndividually  managed  after  PCI.  These  results  may,  however,
e  overestimated  due  to  uncontrolled  bias.  A  dedicated  trial
ocusing  on  high-risk  patients  is  required  before  deﬁnitively
odifying  our  practice.
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